Edgewise Therapeutics, Inc.
EWTX
Rang în acțiuni
#4060
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Preț acțiune
$37.15
Ultima sincronizare: 2026-10-16
Capitalizare de piață
$4.00B
Schimbare (1 zi)
-2.75%
Schimbare (1 an)
146.68%
Țară
US
Tranzacționează Edgewise Therapeutics, Inc. (EWTX)
Categorie
Healthcare
EPS pentru Edgewise Therapeutics, Inc. (EWTX)
EPS la data de June 2026 TTM: $-1.85
Conform celor mai recente rapoarte financiare și prețului acțiunilor Edgewise Therapeutics, Inc., EPS-ul actual al companiei (TTM) este $-1.85. La sfârșitul anului 2023, compania avea un EPS de $-1.57 o creștere față de EPS-ului din 2022, care a fost de $-1.26.
Istoricul EPS pentru Edgewise Therapeutics, Inc. din 2019 până în 2026
EPS la sfârșitul fiecărui an
| An | EPS | Schimbă |
|---|---|---|
| 2026 (TTM) | $-1.85 | 27.59% |
| 2024 | $-1.45 | -7.64% |
| 2023 | $-1.57 | 24.60% |
| 2022 | $-1.26 | 46.51% |
| 2021 | $-0.86 | 145.71% |
| 2020 | $-0.35 | 84.21% |
| 2019 | $-0.19 | 0.00% |
EPS pentru companii similare sau concurente
| Companie | EPS | Diferență EPS | Țara |
|---|---|---|---|
| $17.32 | -1,036.22% |
US
|
|
| $-7.98 | 331.35% |
US
|
|
| $-5.29 | 185.95% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,599.46% |
NL
|
